Compare Cadence Design Systems Inc (CDNS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs ResMed Inc. — how do they compare? Cadence Design Systems Inc trades at $323.06 (market cap $90.20B), while ResMed Inc. trades at $225.67 (market cap $32.61B). The key difference: Cadence Design Systems Inc is far larger — about 2.8× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Cadence Design Systems Inc pays none. Which is the better fit depends on your goals.
| CDNS | RMD | |
|---|---|---|
Market Cap | $90.20B | $32.61B |
Sector | Technology | Health |
52-Week High | $416.39 | $293.73 |
52-Week Low | $265.66 | $182.82 |
Enterprise Value | $91.41B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $326.75, down 1.55% amid a bearish technical signal, though strong fundamentals persist with Q2 2026 earnings beating estimates and AI-driven backlog hitting $8.1B. Revenue growth accelerated to 24% year-over-year, while profitability remains robust with 85.87% gross margins. The stock faces near-term pressure from technical indicators but maintains strong analyst support with an $415.11 consensus target.
The outlook remains positive given Cadence's leadership in semiconductor design software and exposure to AI growth, though high valuations (P/E 65.12) and technical bearishness pose risks. Investor sentiment is buoyed by record backlog and raised 2026 guidance, but competition and macroeconomic sensitivity could challenge further upside.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
